{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-001811","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.255099+00:00","generated_at":"2026-06-06T01:51:32.897891+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead","bullets":["Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.","Vyleesi net product revenue $2.0M (+98% YoY); completed asset sale to Cosette for up to $171M ($12M upfront).","Cash $9.5M + $2.3M AR at Dec 31, 2023; added $9.2M net from Feb 2024 equity offering.","PL9643 Phase 3 dry eye disease topline data expected Feb 2024; PL8177 UC interim analysis Q2 2024.","Phase 2 obesity (MCR4+GLP-1) and ED (bremelanotide+PDE5i) studies to start 1H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-001811","json":"https://secwatch.observer/filing/0001654954-24-001811.json","markdown":"https://secwatch.observer/filing/0001654954-24-001811.md","text":"https://secwatch.observer/filing/0001654954-24-001811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/0001654954-24-001811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:51:32.897891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"401bf1b597d337c4c5831c2e6cc31d29464766e0","claim":"PALATIN TECHNOLOGIES INC reported the fiscal second quarter ended December 31, 2023 results: revenue $4.3 million.","evidence_excerpt":"consists of gross product sales of Vyleesi, net of allowances and accruals. Vyleesi gross product sales to pharmacy distributors for the quarter ended December 31, 2023 were $4.3 million, with net product reven","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/0001654954-24-001811-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended December 31, 2023"},{"label":"Revenue","value":"$4.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}